Membrane (LHR) [DEDS-0242] at Dr. Essa Lab

Membrane (LHR) [DEDS-0242] at Dr. Essa Lab

The Membrane (LHR) [DEDS-0242] test is a highly specialized, advanced laboratory investigation offered at Dr. Essa Lab, one of Pakistan’s premier diagnostic and laboratory networks. This diagnostic test utilizes state-of-the-art membrane-based technology to perform a functional Leukocyte Histamine Release (LHR) assay or evaluate specific membrane-bound receptor activities. By analyzing the functional response of a patient’s circulating white blood cells—specifically basophils—upon exposure to various immunological triggers, this test provides invaluable clinical insights into type I hypersensitivity reactions, autoimmune disorders, and receptor-mediated sensitivities. Dr. Essa Lab, founded by the renowned microbiologist Prof. Dr. Essa Abdulla, has been at the forefront of diagnostic excellence in Karachi and across Pakistan since 1987. Performing the Membrane (LHR) [DEDS-0242] test at this esteemed institution ensures that patients and referring physicians receive the highest standard of analytical precision, clinical accuracy, and professional interpretation.

How the Membrane (LHR) [DEDS-0242] works is deeply rooted in cellular immunology. In a healthy immune system, basophils and mast cells express high-affinity IgE receptors (FcεRI) on their cell membranes. When these membrane-bound receptors are cross-linked by specific allergens or autoantibodies, it triggers a cascade of intracellular signals leading to degranulation and the rapid release of chemical mediators, primarily histamine. The Membrane (LHR) assay isolates the patient’s leukocytes and exposes them to specific antigens or patient serum on a specialized membrane substrate. The amount of histamine released is then quantitatively measured using highly sensitive fluorometric or enzyme-linked immunosorbent assay (ELISA) techniques. This functional in vitro approach offers a safe, controlled environment to evaluate a patient’s allergic and autoimmune profile without the inherent risks of in vivo allergen challenges, such as systemic anaphylaxis.

The clinical importance of the Membrane (LHR) [DEDS-0242] test lies in its ability to bridge the gap between simple sensitization and true functional reactivity. Traditional allergy tests, such as serum-specific IgE tests, merely detect the presence of circulating antibodies but do not confirm whether these antibodies actually trigger cellular activation. By measuring actual histamine release, the Membrane (LHR) test confirms the functional significance of these antibodies. This diagnostic value is particularly crucial for patients suffering from complex, treatment-resistant allergic symptoms, chronic idiopathic urticaria, or suspected drug and food hypersensitivities where standard testing has yielded ambiguous or contradictory results.

Clinical Procedure: What to Expect

Patient Preparation

To ensure the utmost accuracy of the Membrane (LHR) [DEDS-0242] test, strict adherence to patient preparation guidelines is essential. Because this is a functional cellular assay, certain medications can suppress leukocyte activation or inhibit histamine release, leading to false-negative results. Patients must follow these preparation steps carefully:

• Medication Discontinuation: Under the direct supervision of your referring physician, temporarily discontinue medications that interfere with basophil activation. First-generation and second-generation antihistamines must typically be stopped for 3 to 7 days prior to the test.
• Corticosteroids and Immunosuppressants: Systemic corticosteroids (such as oral prednisolone) and other immunosuppressive agents can suppress immune cell function. Discuss with your doctor the appropriate window for tapering or pausing these medications, usually at least 7 to 14 days before testing.
• Tricyclic Antidepressants: Certain antidepressants possess strong antihistamine properties and should be discontinued under medical guidance for several days before the blood draw.
• Dietary Restrictions: While strict fasting is generally not required, patients are advised to avoid high-histamine foods (such as aged cheeses, fermented foods, and processed meats) and alcohol for 24 hours prior to the test to maintain a stable baseline.
• Hydration: Drink plenty of water before your appointment to ensure optimal hydration, which facilitates an easier and more comfortable venipuncture process.

During the Procedure

The collection of the sample for the Membrane (LHR) [DEDS-0242] test is a straightforward outpatient procedure performed by Dr. Essa Lab’s experienced phlebotomists. The process is designed to maximize patient comfort and preserve the viability of the circulating leukocytes:

• Patient Positioning: You will be seated comfortably in a specialized blood collection chair. The phlebotomist will ask you to extend your arm and rest it on a supportive cushion.
• Site Selection and Cleansing: The phlebotomist will inspect your arm to locate a suitable vein, typically in the antecubital fossa (the bend of the elbow). The selected site is thoroughly cleansed with a sterile antiseptic swab and allowed to air dry.
• Tourniquet Application: A soft elastic tourniquet is applied around your upper arm to temporarily restrict blood flow, making the veins more prominent and easier to access.
• Venipuncture: A sterile, single-use needle is gently inserted into the vein. You may feel a brief, mild pinch or stinging sensation. The blood is drawn into specialized collection tubes containing anticoagulants (such as heparin or acid-citrate-dextrose) that preserve cell viability.
• Sample Handling: Because the Membrane (LHR) test requires live, functional leukocytes, the collected blood sample must never be frozen or exposed to extreme temperatures. It is maintained at room temperature and transported immediately to the specialized immunology laboratory at Dr. Essa Lab for prompt processing.
• Post-Draw Care: Once the required volume of blood is collected, the needle is gently removed, and immediate pressure is applied to the puncture site with a sterile cotton ball. A small adhesive bandage is applied to prevent bleeding and protect the site.

When is a Membrane (LHR) [DEDS-0242] Performed?

Evaluation of Chronic Autoimmune Urticaria

Chronic urticaria, characterized by hives and swelling lasting longer than six weeks, often has an underlying autoimmune etiology. In approximately 30% to 40% of these patients, the condition is driven by functional autoantibodies directed against the high-affinity IgE receptor (FcεRI) or IgE itself on the basophil membrane. Physicians request the Membrane (LHR) [DEDS-0242] test to detect these functional autoantibodies. By incubating donor basophils with the patient’s serum, the test measures whether the serum induces significant histamine release, confirming an autoimmune mechanism and guiding targeted therapies such as immunomodulators or monoclonal antibodies.

Investigation of Severe, Unexplained Type I Hypersensitivity

Patients who experience recurrent, severe allergic symptoms or unexplained anaphylaxis require a comprehensive diagnostic workup to identify specific triggers. When standard skin prick testing is deemed too risky due to the danger of inducing systemic anaphylaxis, or when in vitro specific IgE tests are inconclusive, the Membrane (LHR) [DEDS-0242] test provides a safe and highly sensitive alternative. It allows clinicians to test multiple suspected allergens simultaneously in a controlled laboratory environment, pinpointing the exact triggers responsible for the patient’s severe clinical symptoms.

Monitoring Allergen Immunotherapy (AIT) Response

Allergen Immunotherapy (AIT), or desensitization therapy, is a long-term treatment aimed at modifying the immune system’s response to specific allergens. To assess the clinical efficacy of this therapy, physicians utilize the Membrane (LHR) [DEDS-0242] test to monitor changes in cellular reactivity over time. A successful immunotherapy regimen typically results in a progressive reduction of basophil sensitivity and a decrease in histamine release upon allergen challenge. This functional monitoring helps clinicians customize allergen dosages and determine the optimal duration of the treatment.

Diagnosis of Complex Drug and Vaccine Hypersensitivities

Hypersensitivity reactions to pharmaceutical agents, such as beta-lactam antibiotics, neuromuscular blocking agents, or vaccine components, present a significant clinical challenge. Skin testing for drug allergies can be unreliable or carry systemic risks, while standard serological tests are often unavailable. The Membrane (LHR) [DEDS-0242] test serves as an invaluable diagnostic tool by exposing the patient’s leukocytes to the suspected drug compound in vitro. A positive histamine release response confirms drug-specific cellular activation, allowing physicians to safely identify alternative therapeutic agents.

Diagnostic Workup for Food and Hymenoptera Venom Allergies

Allergies to foods (such as peanuts, tree nuts, and shellfish) and Hymenoptera venom (bee and wasp stings) can cause life-threatening systemic reactions. The Membrane (LHR) [DEDS-0242] test is highly effective in differentiating between clinical allergy and asymptomatic sensitization. By measuring the precise threshold of histamine release when leukocytes are exposed to varying concentrations of food or venom proteins, the test assists allergists in evaluating the severity of the allergy, predicting the likelihood of systemic reactions, and making informed decisions regarding oral food challenges.

What Does a Membrane (LHR) [DEDS-0242] Detect?

The Membrane (LHR) [DEDS-0242] test is designed to detect a wide array of functional cellular responses and pathological markers, including:

• Functional autoantibodies targeting the high-affinity IgE receptor (FcεRI) on the cell membrane.
• Autoantibodies directed against membrane-bound IgE molecules.
• Basophil hyper-reactivity to environmental inhalant allergens (e.g., pollens, dust mites, animal dander).
• Cellular sensitivity to specific food proteins and dietary antigens.
• Hypersensitivity reactions to pharmaceutical compounds and therapeutic drugs.
• Sensitization to Hymenoptera venom proteins (bee, wasp, and hornet venoms).
• Basophil activation triggered by occupational chemicals and hapten-protein complexes.
• Elevated spontaneous histamine release, indicating intrinsic cellular or membrane instability.
• Normal or baseline histamine release, ruling out specific IgE-mediated cellular activation.
• Impaired leukocyte viability or basophil anergy (lack of response to positive controls).
• Dose-dependent cellular activation patterns across varying allergen concentrations.
• Cross-reactivity profiles between structurally related allergen groups.
• Reduction in cellular allergen sensitivity following successful desensitization therapy.
• Inhibitory effects of therapeutic monoclonal antibodies (such as omalizumab) on receptor binding.
• Atypical membrane receptor density or altered receptor-ligand binding kinetics.
• Non-specific histamine release caused by physical or chemical membrane disruption.
• Cellular tolerance to previously reactive environmental or dietary antigens.
• Sub-clinical sensitization in patients presenting with atypical or mild symptoms.
• Functional activation of basophils in response to vaccine excipients or adjuvants.
• The presence of circulating factors that modulate or suppress histamine release pathways.

Turnaround Time and Report Access at Dr. Essa Lab

At Dr. Essa Lab, the processing of specialized functional assays like the Membrane (LHR) [DEDS-0242] is conducted with the utmost care and precision. Because this test requires the isolation of live leukocytes, immediate incubation, and highly sensitive quantitative analysis, the turnaround time is typically a few working days. This timeframe ensures that all quality control protocols are rigorously met and that the final report is thoroughly reviewed and signed by a consultant pathologist.

Patients and referring physicians can access reports seamlessly through Dr. Essa Lab’s advanced digital infrastructure. Once the report is finalized, an automated SMS notification is sent to the patient’s registered mobile number. Reports can be viewed, downloaded, and printed directly from the official Dr. Essa Lab website or via their user-friendly mobile application by entering the unique Patient Lab ID and password provided on the receipt. For those who prefer physical copies, high-quality printed reports can be collected from any of the numerous Dr. Essa Lab diagnostic centers located conveniently across Karachi and other major cities.

Membrane (LHR) [DEDS-0242] Findings Overview

Structure / Parameter Evaluated	Normal Findings	Possible Abnormal Findings
Basophil Histamine Release (Allergen Challenge)	Low or negligible release (<10% of total histamine content)	Significant, dose-dependent release (>15-20%), indicating specific IgE-mediated allergy.
Autoantibody Activity (Anti-FcεRI / Anti-IgE)	Negative (no significant histamine release induced in donor basophils)	Positive (induction of histamine release in donor basophils, confirming autoimmune urticaria).
Positive Control Response (fMLP / Anti-IgE)	Robust and expected histamine release (>50% of total content)	Flat or absent response, indicating basophil anergy, cellular exhaustion, or non-viable sample.
Negative Control Response (Buffer Baseline)	Minimal spontaneous histamine release (<5% of total content)	Elevated spontaneous release, indicating intrinsic cellular instability or pre-activation.
Drug / Hapten Challenge	No significant cellular activation or histamine release	Marked histamine release, confirming drug-specific cellular hypersensitivity.
Leukocyte Membrane Integrity	Intact, viable cell membranes with normal receptor density	Fragile or damaged membranes leading to non-specific leakage of intracellular mediators.
Receptor Binding Capacity	Normal ligand-receptor binding and intracellular signaling kinetics	Impaired or blocked receptor binding due to autoantibodies or therapeutic drug interference.

Note: Diagnostic findings should always be interpreted by a qualified healthcare professional together with the patient’s symptoms, medical history, physical examination, laboratory investigations, previous imaging studies, and other relevant clinical information. Additional investigations or specialist consultation may be recommended depending on the findings.

Why Choose Dr. Essa Lab for Membrane (LHR) [DEDS-0242]?

• Experienced healthcare professionals: Dr. Essa Lab features a team of highly qualified consultant pathologists, immunologists, and laboratory technologists specializing in advanced cellular assays.
• Patient-focused care: Dedicated to providing a compassionate, seamless, and comfortable diagnostic experience for every patient from sample collection to report delivery.
• Quality diagnostic services: Adheres to strict international quality control standards and laboratory protocols to ensure the highest level of clinical accuracy.
• Professional reporting: Comprehensive, detailed, and easy-to-understand diagnostic reports that provide clear clinical guidance for referring physicians.
• Modern diagnostic approach: Utilizes advanced laboratory technologies and specialized membrane-based assays to support complex clinical decision-making.
• Comfortable environment: Clean, modern, and hygienic collection centers designed with patient comfort, safety, and privacy in mind.
• Convenient location: A vast network of branches across Karachi and other major cities, making premium diagnostic services easily accessible to all.
• Commitment to accurate diagnosis: Dedicated to delivering reliable, evidence-based results that healthcare providers trust for effective patient management.